COVID-19 studies for: C19 studies:  HC QHC Q IvermectinIVM Vitamin DVitamin D ZincZn REGN-COV2REGN LY-CoVLY RemdesivirRMD
HC Q study #150
Source   PDF   Share   Tweet
See all 181 studies
10/21
Positive
Late treatment study
Ñamendys-Silva et al., Heart & Lung, doi:10.1016/j.hrtlng.2020.10.013 (Peer Reviewed)
Outcomes of patients with COVID-19 in the Intensive Care Unit in Mexico: A multicenter observational study
Retrospective 164 ICU patients in Mexico showing 32% lower mortality with HC Q+AZ and 37% lower with C Q.
HC Q+AZ vs. neither HC Q or C Q relative risk RR 0.68, p = 0.03
C Q vs. neither HC Q or C Q relative risk RR 0.63, p = 0.02
HC Q+AZ or C Q vs. neither relative risk RR 0.65, p = 0.006
death, ↓32.3%, p=0.18, HCQ+AZ vs. neither HCQ or CQ
death, ↓37.1%, p=0.09, CQ vs. neither HCQ or CQ
death, ↓34.5%, p=0.006, HCQ+AZ or CQ
Source   PDF   Share   Tweet
See all 181 studies
Please send us corrections, updates, or comments.
Submit